0
Errata |

Errata and Addendum FREE TO VIEW

Chest. 2008;134(2):473-474. doi:
Text Size: A A A
Published online

In the May 1975 issue, the article “Pulmonary Atresia with Ventricular Septal Defect: Report of the Oldest Known Surviving Case” (), reported on an unusual case of pseudotruncus arteriosus. It has recently been reported to CHEST by a physician who subsequently treated the patient and who saw the post mortem examination results that the patient died of truncus arteriosus.

In the June 2008 supplement, in three articles in which Holger Schünemann is author or coauthor, “Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (); “Methodology for Antithrombotic and Thrombolytic Therapy Guideline Development: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (); and “Grades of Recommendation for Antithrombotic Guidelines: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (), the Conflict of Interest statement that appears at the end of the text in the print edition is wrong. It has been updated in the online edition and those versions of the articles should be used. The Conflict of Interest statement in each article should read: Dr. Schünemann reports no personal payments from for-profit organizations, but he received research grants and/or honoraria that were deposited into research accounts or received by a research group that he belongs to from AstraZeneca (research grant, honoraria), Amgen (research grant), Barilla (research grant), Chiesi Foundation (honorarium), Lily (honorarium), Pfizer (research grant, honorarium), Roche (honorarium) and UnitedBioSource (honorarium) for development or consulting regarding quality of life instruments for chronic respiratory diseases and as lecture fees related to the methodology of evidence based practice guideline development and/or research methodology. He is documents editor for the American Thoracic Society and senior editor of the American College of Chest Physicians Antithrombotic and Thrombolytic Therapy Guidelines and both organizations receive funding from for-profit organizations. Other institutions or organizations that he is affiliated with likely receive funding from for-profit sponsors that are supporting infrastructure and research that may serve his work.

In the June 2008 supplement, in the article by Hirsh et al, “Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (), on page 153S, first column, second paragraph under Argatroban, the final sentence should read: “Argatroban is given as a continuous IV infusion at a dose of 2 μg/kg/min, and the dose is adjusted to maintain the APTT ratio in the 1.5 to 3.0 range.”

In the June 2008 supplement, in the article by Weitz et al, “New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (), Figure 2, on page 240S contained formatting errors: this is how it should appear:

Addendum

In the June 2008 supplement, in the article by Hirsh et al, “Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (), on page 153S, first column, second paragraph under Argatroban, the authors wish to add the following clarifying language:

The recommended dosage for patients undergoing percutaneous coronary interventions in HIT/HITTS Patients: Initial dosage: An infusion of argatroban should be started at 25 μg/kg/min and a bolus of 350 μg/kg administered via a large bore intravenous (IV) line over 3 to 5 min (see Table 9 from the argatroban prescribing information). Activated clotting time (ACT) should be checked 5 to 10 min after the bolus dose is completed. The procedure may proceed if the ACT is greater than 300 s.

Dosage adjustment: If the ACT is less than 300 s, an additional IV bolus dose of 150 μg/kg should be administered, the infusion dose increased to 30 μg/kg/min, and the ACT checked 5 to 10 min later (see Table 9 from the argatroban prescribing information). If the ACT is greater than 450 s, the infusion rate should be decreased to 15 μg/kg/min, and the ACT checked 5 to 10 min later (see Table 9 from the argatroban prescribing information). Once a therapeutic ACT (between 300 and 450 s) has been achieved, this infusion dose should be continued for the duration of the procedure.


Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543